D-dimer

LumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England’s First Heart & Lung Screening Hub

Retrieved on: 
Friday, October 20, 2023
Patient, RSV, Intelligence, AstraZeneca, Liverpool University Hospitals NHS Foundation Trust, Everton F.C., Heart, Medicine, Mortality, Bureau of Oceans and International Environmental and Scientific Affairs, Health, Glycated hemoglobin, Partnership, Asthma, Phlebotomy, Community, D-dimer, Anxiety, Diagnosis, Chronic obstructive pulmonary disease, Heart failure, COPD, CRP, Platform, Mental health, Medical device, Pharmaceutical industry, Medical imaging

The LumiraDx NT-proBNP test is the only NT-proBNP test currently available that can be used with a simple fingerstick sample.

Key Points: 
  • The LumiraDx NT-proBNP test is the only NT-proBNP test currently available that can be used with a simple fingerstick sample.
  • *
    LONDON, Oct. 20, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, is pleased to announce a strategic collaboration with AstraZeneca and Everton in the Community to set up England’s first community-based heart and lung screening hub, set to go live in November.
  • The official charity of Everton Football Club will run this novel screening hub from the recently opened People’s Place.
  • The strategic partnership with AstraZeneca and Everton in the Community will also work closely with Liverpool University Hospitals NHS Foundation Trust and next generation medical technology providers Lenus Health, Us2.ai and ArtiQ.

LumiraDx’s Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and Tests

Retrieved on: 
Monday, July 31, 2023
Partnership, SARS-CoV-2, INR, Hospital, D-dimer, RSV, CRP, N-terminal prohormone of brain natriuretic peptide, Patient, Glycated hemoglobin, Video game

Partnership between LumiraDx and Axonlab will allow Axonlab to sell the unique LumiraDx Point of Care testing solution and give LumiraDx the ability to expand the reach of the LumiraDx Platform and tests.

Key Points: 
  • Partnership between LumiraDx and Axonlab will allow Axonlab to sell the unique LumiraDx Point of Care testing solution and give LumiraDx the ability to expand the reach of the LumiraDx Platform and tests.
  • Under the terms of the distribution agreement, LumiraDx has granted Axonlab the right to promote, market, and sell the LumiraDx Platform and tests to hospitals, doctors, clinics, private laboratories and research institutions in the aforementioned countries.
  • "We are excited to partner with LumiraDx for the commercial distribution of the LumiraDx Platform in Switzerland and Germany,” said Lukas Hadorn CEO of Axonlab.
  • With the new distribution agreement for Switzerland and Germany, the Axonlab collaboration adds two important markets to our distribution portfolio and will allow us to accelerate the commercial roll-out of our unique LumiraDx Platform.

LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK

Retrieved on: 
Tuesday, January 31, 2023
Glycated hemoglobin, N-terminal prohormone of brain natriuretic peptide, Diagnosis, CRP, Heart, Health, RSV, Peptide, Heart failure, Patient, INR, Medtronic, Organic, D-dimer, CHF, POC, Medical device

Run on the highly portable LumiraDx Platform, the LumiraDx NT-proBNP test is a quantitative, fingerstick blood assay designed for near-patient testing with lab-comparable results in 12 minutes.

Key Points: 
  • Run on the highly portable LumiraDx Platform, the LumiraDx NT-proBNP test is a quantitative, fingerstick blood assay designed for near-patient testing with lab-comparable results in 12 minutes.
  • LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced it has commenced commercial shipment of its point of care NT-proBNP test to aid in the diagnosis of CHF across Europe.
  • The LumiraDx NT-proBNP test is currently the only quantitative direct fingerstick NT-proBNP assay commercially available, which can enable access to NT-proBNP testing in the community.
  • The Your Heart Matters Bus initiative is a perfect example of how the LumiraDx technology can truly bring lab comparable diagnostics to the community.”

Global Hemostasis Diagnostics Market to Reach $2.7 Billion by 2027 with a 4.8% CAGR - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 24, 2022
Medical Devices, Other Health, Health, Health Technology, Medical Supplies, D-dimer, Growth, COVID-19, Hemostasis, Pet

In the changed post COVID-19 business landscape, the global market for Hemostasis Diagnostics estimated at US$2 Billion in the year 2020, is projected to reach a revised size of US$2.7 Billion by 2027, growing at a CAGR of 4.8% over the analysis period 2020-2027.

Key Points: 
  • In the changed post COVID-19 business landscape, the global market for Hemostasis Diagnostics estimated at US$2 Billion in the year 2020, is projected to reach a revised size of US$2.7 Billion by 2027, growing at a CAGR of 4.8% over the analysis period 2020-2027.
  • Prothrombin Test Time (PT), one of the segments analyzed in the report, is projected to record a 4.5% CAGR and reach US$1.1 Billion by the end of the analysis period.
  • China, the world's second largest economy, is forecast to reach a projected market size of US$561.5 Million by the year 2027 trailing a CAGR of 8.5% over the analysis period 2020 to 2027.
  • In the global Fibrinogen segment, USA, Canada, Japan, China and Europe will drive the 4.9% CAGR estimated for this segment.

Todos Medical Announces Positive Biomarker Data from Phase 2 Trial of Tollovir in Hospitalized COVID-19 Patients

Retrieved on: 
Thursday, June 30, 2022
MERS, Patient, Research, Neurodegeneration, Legislation, GLOBE, COVID-19, Company, CRP, Immune system, Shaare Zedek Medical Center, D-dimer, EUA, Cancer immunotherapy, Severe acute respiratory syndrome coronavirus 2, Cell cycle, Knowledge, Apoptosis, TMB-2, OTCQB, Pressure, Monocyte, Neuron, Solution, Alzheimer's disease, Emergency Use Authorization, CEO, Biotechnology, COVID, Brain, TBIA, IC50, Inflammation, Technology, IL-6, Virus, PCR, US Foods, Ivermectin, Method, Review, Biomarker, U.S. Securities and Exchange Commission, Plasma, Lymphocyte, Synthase, Literature, Cancer, Pharmaceutical industry, Medical imaging, Delta, Pharma

New York, NY, and Tel Aviv, ISRAEL, June 30, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced biomarker data from its majority-owned joint venture 3CL Pharma Ltd.’s Phase 2 clinical trial of Tollovir™ in hospitalized COVID-19 patients. The data showed a positive correlation between the clinical data announced for Tollovir on January 27, 2022 and biomarkers associated with acute phase immune response (IL-6), inflammation (C reactive protein), blood clotting (D-dimer) and immune response to COVID-19 (cPass neutralizing antibodies). Additionally, renal and hepatic biomarker data showed no signals of treatment-associated risk with Tollovir therapy.

Key Points: 
  • Additionally, renal and hepatic biomarker data showed no signals of treatment-associated risk with Tollovir therapy.
  • Recent peer reviewed literature shows the predictability of key biomarker data such as IL-6, CRP, and D-Dimer in the hospitalized setting.
  • We believe the correlative biomarker data, in addition to the positive clinical results previously reported in hospitalized patients primarily from the Delta variant wave,should elevate Tollovirs profile in the eyes of regulators, said Gerald Commissiong, President & CEO of Todos Medical and Interim-CEO of 3CL Pharma.
  • Tollovir has successfully completed a Phase 2 clinical trial in Israel for the treatment of patients hospitalized with COVID-19.

LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test

Retrieved on: 
Thursday, June 2, 2022
Clinical prediction rule, VTE, INR, CHF, D-dimer, Pharmacy, Research, School, Heart, RSV, Deep vein thrombosis, Annual report, Health care, Platform, Security (finance), Disease, CE, Electric Bond and Share Company v. Securities and Exchange Commission, Solution, Multimedia, Heart failure, Physician, CRP, N-terminal prohormone of brain natriuretic peptide, Peptide, Risk, Patient, Pulmonary embolism, Glycated hemoglobin, DVT, Diabetes, Laboratory, Private Securities Litigation Reform Act, Infection, COVID-19, Thrombosis, Diagnosis, SEC, Severe acute respiratory syndrome coronavirus 2, Degenerative disease, Ambulatory, POC, Emergency, Health, View, Medical device, Pharmaceutical industry

The LumiraDx NT-proBNPand the LumiraDx D-Dimer tests are currently the only quantitative direct fingerstick assays produced for each test.

Key Points: 
  • The LumiraDx NT-proBNPand the LumiraDx D-Dimer tests are currently the only quantitative direct fingerstick assays produced for each test.
  • D-Dimer testing is widely accepted as the first step in the management of patients suspected of VTE.
  • LumiraDx has, on the market and in development, 30+ tests covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, all on the LumiraDx Platform.
  • In addition, LumiraDx has a comprehensive portfolio of fast, accurate, and cost-efficient COVID-19 testing solutions from the lab to point of need.

LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test

Retrieved on: 
Thursday, June 2, 2022
Clinical prediction rule, VTE, INR, CHF, D-dimer, Pharmacy, Research, School, Heart, RSV, Deep vein thrombosis, Annual report, Health care, Platform, Security (finance), Disease, CE, Electric Bond and Share Company v. Securities and Exchange Commission, Solution, Heart failure, Physician, CRP, N-terminal prohormone of brain natriuretic peptide, Peptide, Risk, Patient, Pulmonary embolism, Glycated hemoglobin, DVT, Diabetes, Laboratory, Private Securities Litigation Reform Act, Infection, COVID-19, Thrombosis, Diagnosis, SEC, Severe acute respiratory syndrome coronavirus 2, Degenerative disease, Ambulatory, POC, Emergency, Health, Medical device, Pharmaceutical industry

The LumiraDx NT-proBNPand the LumiraDx D-Dimer tests are currently the only quantitative direct fingerstick assays produced for each test.

Key Points: 
  • The LumiraDx NT-proBNPand the LumiraDx D-Dimer tests are currently the only quantitative direct fingerstick assays produced for each test.
  • D-Dimer testing is widely accepted as the first step in the management of patients suspected of VTE.
  • LumiraDx has, on the market and in development, 30+ tests covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, all on the LumiraDx Platform.
  • In addition, LumiraDx has a comprehensive portfolio of fast, accurate, and cost-efficient COVID-19 testing solutions from the lab to point of need.

Global D-dimer Testing Market Industry Analysis Report 2021-2028 - A US$1.83 Billion Market by 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 18, 2021
Medical devices, Health, Biotechnology, Branches of biology, Chemical pathology, D-dimer, Fibrinolytic system, Aptamer, Market segmentation, Market share, Articles, Life sciences

The "D-dimer Testing Market Share, Size, Trends, Industry Analysis Report, By Product; By Testing Method; By Application; By End-Use; By Regions; Segment Forecast, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "D-dimer Testing Market Share, Size, Trends, Industry Analysis Report, By Product; By Testing Method; By Application; By End-Use; By Regions; Segment Forecast, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global D-dimer testing market is expected to reach US$1.83 billion by 2028.
  • The global market for D-dimer testing is fragmented based on the product, method, application, end-use, and region.
  • The reagents & consumables market segment accounted for the largest revenue share of the global D-dimer testing industry in 2020 owing to the availability of ready made aptamers.

Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with VASCEPA® (Icosapent Ethyl) in Late Breaker Presentation at National Lipid Association (NLA) Scientific Sessions 2020

Retrieved on: 
Sunday, December 13, 2020
Clinical medicine, Branches of biology, Medicine, Chemical pathology, Biomarkers, Blood tests, Amarin Corporation, Ethyl eicosapentaenoic acid, D-dimer, C-reactive protein

The primary biomarker endpoint of the study was within-group changes in high-sensitivity C-reactive protein (hsCRP), a measure of inflammation.

Key Points: 
  • The primary biomarker endpoint of the study was within-group changes in high-sensitivity C-reactive protein (hsCRP), a measure of inflammation.
  • VASCEPA administration resulted in a 25% reduction in hsCRP (p=0.011) as well as a reduction in D-dimer (p=0.048).
  • VASCEPA CardioLink-9 Study is an investigator-initiated study supported by Amarin and by HLS Therapeutics, Inc.
  • This presentation of CardioLink-9 study results was one of multiple data presentations at the NLA Scientific Sessions supported by Amarin.

Global D-dimer Testing Industry

Retrieved on: 
Wednesday, November 18, 2020
Chemical pathology, D-dimer, Fibrinolytic system

US D-dimer Testing Market Share (in %) by Company: 2019 & 2025

Key Points: 
  • US D-dimer Testing Market Share (in %) by Company: 2019 & 2025
    Projections in US$ Thousand by Testing Method: 2020 to 2027
    in US$ Thousand by Application: 2020 to 2027
    Forecasts in US$ Thousand by Testing Method: 2020 to 2027
    Testing Method in US$ Thousand: 2012-2019
    Table 30: D-dimer Testing Market in Canada: Percentage Share
    Breakdown of Sales by Testing Method for 2012, 2020, and 2027
    Analysis in US$ Thousand by Application: 2020 to 2027
    Table 32: D-dimer Testing Market in Canada: Summarization of
    Table 34: Japanese Market for D-dimer Testing: Annual Sales
    Table 35: D-dimer Testing Market in Japan: Historic Sales
    Testing in US$ Thousand by Application: 2020 to 2027
    US$ Thousand by Testing Method: 2012-2019
    Table 42: Chinese D-dimer Testing Market by Testing Method:
    Percentage Breakdown of Sales for 2012, 2020, and 2027
    Table 47: D-dimer Testing Market in Europe: A Historic Market
    Forecasts in US$ Thousand by Testing Method: 2020-2027
    Opportunity in US$ Thousand by Application: 2020-2027
    Table 53: D-dimer Testing Market in Europe: Summarization of
    Table 55: D-dimer Testing Market in France by Testing Method:
    US$ Thousand by Testing Method: 2012-2019
    France in US$ Thousand by Application: 2020-2027
    Table 60: French D-dimer Testing Market Share Analysis:
    A 17-Year Perspective by Application for 2012, 2020, and 2027
    Table 61: D-dimer Testing Market in Germany: Recent Past,
    US$ Thousand by Testing Method: 2012-2019
    Table 64: D-dimer Testing Market in Germany: Annual Sales
    US$ Thousand by Testing Method: 2012-2019
    Table 69: Italian D-dimer Testing Market by Testing Method:
    Percentage Breakdown of Sales for 2012, 2020, and 2027
    Table 73: United Kingdom Market for D-dimer Testing: Annual
    Table 74: D-dimer Testing Market in the United Kingdom:
    D-dimer Testing in US$ Thousand by Application: 2020 to 2027
    Forecasts in US$ Thousand by Testing Method: 2020-2027
    Opportunity in US$ Thousand by Application: 2020-2027
    Table 83: D-dimer Testing Market in Rest of Europe:
    in US$ Thousand by Testing Method: 2012-2019
    Asia-Pacific in US$ Thousand by Application: 2020-2027
    in US$ Thousand by Application: 2012-2019
    Table 90: Asia-Pacific D-dimer Testing Market Share Analysis:
    A 17-Year Perspective by Application for 2012, 2020, and 2027
    Forecasts in US$ Thousand by Testing Method: 2020 to 2027
    by Testing Method in US$ Thousand: 2012-2019
    Table 93: D-dimer Testing Market in Rest of World: Percentage
    Share Breakdown of Sales by Testing Method for 2012, 2020, and
    Demand Analysis in US$ Thousand by Application: 2020 to 2027
    Table 95: D-dimer Testing Market in Rest of World: